3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT: NCT00935090 · ACTIVE_NOT_RECRUITING
Brief Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Frequently Asked Questions
What is 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer?
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer is a clinical trial registered under NCT00935090. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT00935090?
The current status of NCT00935090 (3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer) is: ACTIVE_NOT_RECRUITING.
When did 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer start?
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer started on 2009-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.